Novavax (NVAX) COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial

Go back to Novavax (NVAX) COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
Novavax, Inc. (NASDAQ: NVAX) Delayed: 248.16 -9.14 (3.55%)
Previous Close $257.30    52 Week High $9.23 
Open $257.30    52 Week Low $1.16 
Day High $257.30    P/E N/A 
Day Low $246.25    EPS $-0.30 
Volume 3,006,354